Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2015 Financial and Business Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Needham & Company Reiterates Buy on Progenics Pharma (PGNX); Anticipates Oral Relistor Approval
March 14, 2016 8:01 AM EDTNeedham & Company reiterated a Buy rating and $11.00 price target on Progenics Pharmaceuticals (NASDAQ: PGNX). Needham is anticipating approval of oral Relistor on its April 19th PDUFA date, which will trigger a $50 million milestone payment from Valeant and should lead to a significant increase in Relistor... More
Progenics Pharma (PGNX) Tops Q4 EPS by 4c
March 11, 2016 8:02 AM ESTProgenics Pharma (NASDAQ: PGNX) reported Q4 EPS of ($0.10), $0.04 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $5.1 million versus the consensus estimate of $2.25 million.
For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.
... More